Update in Lung Cancer 2007
نویسندگان
چکیده
منابع مشابه
Untreated patients in "CT screening for lung cancer: update 2007".
Disclosure: This article discusses the off-label use of computed tomography devices (manufactured by General Electric and others) for screening. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the author, p...
متن کاملResponse to "CT screening for lung cancer: update 2007".
UNDER “KEY CONCEPTS AND DEFINITIONS” 1. The authors tell readers that the staging system for lung cancer “is based on differences in lung cancer survival.” Their reference is to the update on lung cancer staging by Mountain, which states that the lung cancer staging system is based on identifying the intersection of similar treatment options and similar outcome expectations [2]. 2. The authors ...
متن کاملLung cancer screening update
Low-dose computed tomography (ld-CT) for lung cancer screening in high-risk subjects is performed within clinical trials and has started to be used in routine clinical practice. The technique is well defined, even if some methodological problems are still debated, such as the measurements of pulmonary nodules, the size to define them as clinically significant, the management of small or non-sol...
متن کاملLung cancer screening update
Lung cancer is the leading cause of cancer-related mortality globally and the American cancer society estimates approximately 226,160 new cases and 160,340 deaths from lung cancer in the USA in the year 2012. The majority of lung cancers are diagnosed in the later stages which impacts the overall survival. The 5-year survival rate for pathological st age IA lung cancer is 73% but drops to only ...
متن کاملASCO update: lung cancer
In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors offers sequential therapy for patients with mutated non-small-cell lung cancer. Immunotherapy has found its way into clinical routine and presents us with new c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Respiratory and Critical Care Medicine
سال: 2008
ISSN: 1073-449X,1535-4970
DOI: 10.1164/rccm.200801-107up